Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $43.60 Average Price Target from Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have earned an average rating of “Moderate Buy” from the five analysts that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $43.60.

COLL has been the topic of several research analyst reports. Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a report on Friday, January 10th. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Finally, Piper Sandler lowered their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 4th.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $29.66 on Tuesday. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. Collegium Pharmaceutical has a 1-year low of $27.28 and a 1-year high of $42.29. The company has a market capitalization of $933.87 million, a P/E ratio of 12.78 and a beta of 0.99. The firm’s 50 day simple moving average is $30.80 and its two-hundred day simple moving average is $33.15.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The business had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million. Research analysts expect that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Colleen Tupper sold 1,949 shares of the business’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $30.00, for a total value of $58,470.00. Following the sale, the chief financial officer now owns 177,195 shares in the company, valued at approximately $5,315,850. The trade was a 1.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the business’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the completion of the sale, the executive vice president now owns 154,204 shares in the company, valued at $4,330,048.32. This represents a 20.60 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 95,516 shares of company stock worth $2,833,180. Insiders own 3.98% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds have recently added to or reduced their stakes in COLL. New Age Alpha Advisors LLC purchased a new stake in shares of Collegium Pharmaceutical during the fourth quarter valued at about $40,000. TD Private Client Wealth LLC lifted its position in shares of Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after buying an additional 483 shares during the last quarter. Virtus Fund Advisers LLC purchased a new stake in shares of Collegium Pharmaceutical during the third quarter valued at about $72,000. KBC Group NV lifted its position in shares of Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after buying an additional 982 shares during the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in shares of Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 316 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.